Population structure of Leishmania infantum from Morocco

infection, untreated Chagas’disease enters a chronic phase that is initially asymptomatic or unrecognized. Between 2030% of patients develop cardiac abnormalities, 10% digestive complaints, and less than 5% of patients develop a neurologic form of disease. The aim of this work is to determiner the effect of Benznidazol treatment (5 mg/kg/day) 60 days, in patients with chronic Chagas disease. Methods: In 53 samples of patients we were tested by enzyme linked immunoassay (ELISA Dade Behring CHAGO560DB) for IgG antibodies against TC, and indirect immunofluorescence (IFI Biocientifica SA Immunofluor Chagas NF09-60) as confirmatory tes, for IgG (Bio-Merieux 75 692) antibodies, with serial serum dilutions to determine the level of these antibodies. In addition, all PCR were performed before treatment and at the end of it. As a criterion of cure was established a significant (more than 2 degrees) in the rate of antibody after treatment. Results: About the 53 patients studied, 37 were performed two or more determinations of antibodies before and after treatment and in 80% of them, a diminution of the levels were found. The PCR was negative after treatment in all cases. In 13 patients was carried out only antibody titer before treatment, administering it even with low rates from them, because they had organ involvement suggestive of Chagas. Conclusion: More studies are needed to clearly establish the criteria for cure of Chagas disease. Furthermore, because in these patients with chronic Chagas disease parasitaemia sometimes is intermittent and low have to question the result of a negative PCR.